[Autoantibodies in Paraneoplastic Neurological Syndrome]
1Department of Neurology, Brain Research Institute, Niigata University.
Abstract:
Paraneoplastic neurological syndromes (PNS) are caused by immune responses against neuronal antigens expressed by the tumor. Based on the immunological pathomechanisms and responsiveness of treatments, onconeuronal antibodies are divided into two categories: 1) antibodies against neural intracellular antigens and 2) antibodies against neuronal surface or synaptic antigens. The recent discovery of onconeuronal antibodies have radically changed concepts of CNS autoimmunity, including PNS. The recognition of PNS provides a foundation for the early detection of underlying tumors and initiations of prompt treatments, which can result in substantial improvement. We here review the characteristic onconeuronal antibodies, including anti-Hu, anti-Ma2, and anti-N-methyl-D-aspartate receptor, and discuss the algorithm for the diagnosis of PNS.
Insights
Paraneoplastic neurological syndromes (PNS) arise from anti-tumor immune responses targeting the nervous system. Identifying specific onconeuronal antibodies aids early tumor detection and treatment, improving patient outcomes.
Area of Science:
- Neuroimmunology
- Oncology
- Neurology
Background:
- Paraneoplastic neurological syndromes (PNS) result from immune responses to tumor-expressed neuronal antigens.
- Onconeuronal antibodies are classified based on immunological mechanisms and treatment responses into intracellular and surface/synaptic antigen targets.
- Advances in identifying onconeuronal antibodies have significantly reshaped understanding of central nervous system (CNS) autoimmunity and PNS.
Purpose of the Study:
- To review characteristic onconeuronal antibodies, such as anti-Hu, anti-Ma2, and anti-N-methyl-D-aspartate receptor (NMDAR).
- To discuss the diagnostic algorithm for paraneoplastic neurological syndromes.
- To highlight the importance of PNS recognition for early tumor detection and prompt treatment initiation.
Main Methods:
- Literature review of onconeuronal antibodies and their associated neurological syndromes.
- Analysis of immunological pathomechanisms and treatment responsiveness.
- Discussion of diagnostic strategies and algorithms for PNS.
Main Results:
- Onconeuronal antibodies are key biomarkers in PNS, targeting distinct neuronal antigens.
- Specific antibodies like anti-Hu, anti-Ma2, and anti-NMDAR are associated with characteristic clinical syndromes.
- Early detection of PNS through antibody identification facilitates timely diagnosis of underlying malignancies.
Conclusions:
- Recognition and characterization of onconeuronal antibodies are crucial for diagnosing PNS.
- Prompt diagnosis and treatment of PNS can lead to substantial clinical improvement.
- Understanding PNS pathogenesis aids in managing CNS autoimmunity and associated cancers.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Restless Leg Syndrome and Night Terrors
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
Acute Coronary Syndrome V: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management


